NPS Pharmaceuticals Company Profile (NASDAQ:NPSP)

Analyst Ratings

Consensus Ratings for NPS Pharmaceuticals (NASDAQ:NPSP) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for NPS Pharmaceuticals (NASDAQ:NPSP)
Show:
DateFirmActionRatingPrice TargetActions
1/14/2015JPMorgan Chase & Co.DowngradeOverweight -> Neutral$42.00 -> $46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/13/2015Needham & Company LLCDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/13/2015Barclays PLCDowngradeOverweight -> Equal Weight$50.00 -> $46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/12/2015CRT CapitalDowngradeBuy -> Fair ValueView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/12/2015Jefferies GroupSet Price TargetHold$26.00 -> $46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/12/2015WedbushDowngradeOutperform -> Neutral$46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/12/2015Canaccord GenuityDowngradeBuy -> Hold$42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2014Sterne Agee CRTInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/24/2014Goldman Sachs Group Inc.DowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/10/2014FBR & CoBoost Price TargetOutperform$34.00 -> $36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for NPS Pharmaceuticals (NASDAQ:NPSP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
2/18/2015Q414$0.06($0.02)$69.30 million$66.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314$0.01($0.02)$59.50 million$57.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214$0.02$53.06 million$56.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.02)($0.06)$48.30 million$44.04 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413$0.02$0.07$44.22 million$54.45 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2013Q313($0.02)($0.01)$38.40 million$39.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.07)($0.13)$31.62 million$36.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.13)($0.09)$27.56 million$25.43 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/21/2013Q4 2012($0.09)($0.14)$28.93 million$27.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2012Q312($0.16)($0.04)$28.18 million$27.02 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2012($0.09)$0.08ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2012($0.11)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/15/2012($0.11)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2011($0.10)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2011($0.07)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2011($0.12)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/15/2011($0.20)($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NPS Pharmaceuticals (NASDAQ:NPSP)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for NPS Pharmaceuticals (NASDAQ:NPSP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for NPS Pharmaceuticals (NASDAQ:NPSP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/10/2015Susan E GrafVPSell6,711$45.87$307,833.57View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2014Joseph J RogusSVPSell16,467$35.00$576,345.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2014Luke M BesharCFOSell52,258$35.00$1,829,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2014Rachel R SeliskerDirectorSell3,708$34.59$128,259.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014Rachel R SeliskerDirectorSell23,157$34.50$798,916.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/28/2014Rachel R SeliskerDirectorSell11,635$34.50$401,407.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2014Joseph J RogusSVPSell26,782$30.00$803,460.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2014Rachel R SeliskerDirectorSell15,188$29.50$448,046.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/31/2014Luke M BesharCFOSell10,000$29.00$290,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2014Luke M BesharCFOSell30,635$26.75$819,486.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2014Georges GemayelDirectorSell6,188$37.70$233,287.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2014Luke BesharCFOSell31,588$35.01$1,105,895.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2013Luke BesharCFOSell37,874$30.02$1,136,977.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2013James GroningerDirectorSell3,000$29.50$88,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2013Ed StratemeierSVPSell205,432$25.13$5,162,506.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/20/2013Luke BesharCFOSell50,000$30.26$1,513,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Joseph RogusVPSell25,312$28.11$711,520.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Luke BesharCFOSell50,000$27.89$1,394,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/30/2013Roger GarceauCMOSell110,000$25.18$2,769,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2013James GroningerDirectorSell16,900$23.21$392,249.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2013Luke M BesharCFOSell45,150$14.18$640,227.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2012Glenn R MelroseSVPBuy11,000$9.09$99,990.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2012Roger GarceauCMOSell140,625$9.51$1,337,343.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for NPS Pharmaceuticals (NASDAQ:NPSP)
DateHeadline
07/08/16 05:34 PMShire (SHPG) Gets EU Nod for Label Expansion of Revestive
06/27/16 09:43 AMNPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Broker Price Targets For The Coming Week - Fiscal Standard
06/23/16 06:01 PMNPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Current Analyst Ratings - Fiscal Standard
06/03/16 05:59 PMGaps Up Stocks Summary, June 3 - TLOG, RXDX, VLTC, CONN, PL, GIGA, NPSP - FxPips.com
06/03/16 08:21 AMGaps Up Stocks Summary, June 3 – TLOG, RXDX, VLTC, CONN, PL, GIGA, NPSP - The company traded at $3.21 + 2.00 (165.29 pct). NPS Pharmaceuticals Inc. (NPSP) had a gap up of 2.68 pts or 8.61 pct above its previous close of $31.13. The company traded at $35.11 + 3.98 (12.77 pct). ARIAD Pharmaceuticals Inc. (ARIA) had a gap up of 0 ...
05/30/16 03:40 PMA Deep Dive Into Shire's Business - Seeking Alpha - Seeking AlphaA Deep Dive Into Shire's BusinessSeeking AlphaShire has a leading position in rare diseases with a strong portfolio and a decent pipeline. The combination of existing drugs and its pipeline will support the top-line growth and margin expansion. Valuation is compelling despite a higher EPS growth ...
05/30/16 03:40 PMNext Weeks Broker Price Targets For NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) - Share Trading News - Next Weeks Broker Price Targets For NPS Pharmaceuticals, Inc. (NASDAQ:NPSP)Share Trading News01/12/2015 – NPS Pharmaceuticals, Inc. had its “fair value” rating reiterated by analysts at CRT Capital. 01/12/2015 – NPS Pharmaceuticals, Inc. was downgraded to “hold” by analysts at Canaccord Genuity. They now have a USD 42 price target on the stock.and more »
05/01/16 02:04 AMShire Quarterly Profit Tops Estimates as Drug Sales Soar (1) - (Bloomberg) -- Shire Plc reported first-quarter earnings that beat analysts’ estimates as sales climbed for its key ADHD drug and medicines to treat rare diseases obtained in last year’s acquisition of NPS Pharmaceuticals Inc. Earnings per American ...
04/28/16 09:15 PMNPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Updated Broker Price Targets - Share Trading News - NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP). The latest reports which are currently in issue on Thursday 28th of April state 0 analysts have a rating of “strong buy”, 0 ...and more »
04/24/16 04:19 PMNPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Broker Price Targets For The Coming Week - Share Trading News - NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP). The latest reports which are currently in issue on Sunday 24th of April state 0 analysts have a rating of “strong buy”, 0 ...and more »
04/22/16 04:04 PMBroker Roundup For NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) - Share Trading News - Broker Roundup For NPS Pharmaceuticals, Inc. (NASDAQ:NPSP)Share Trading News09/10/2014 – NPS Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 36 price target on the stock. The share price of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) was up +0.00% during the ...and more »
04/11/16 09:07 PMCompany Overview of NPS Pharmaceuticals, Inc. - NPS Pharmaceuticals, Inc., a biopharmaceutical company, provides therapeutic products for the treatment of gastrointestinal and endocrine disorders. The company offers Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are ...
04/08/16 03:56 PMLatest Analyst Reports On NPS Pharmaceuticals, Inc. - Risers & Fallers - Latest Analyst Reports On NPS Pharmaceuticals, Inc.Risers & FallersNPS Pharmaceuticals, Inc. has a 50 day moving average of 0.00 and a 200 day moving average of 37.00. It has a 52-week low of 22.00 and a 52-week high of 46.00. The share price of the company (NASDAQ:NPSP) was unchanged +0.00%, with a high of ...and more »
04/05/16 03:53 PMNPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Updated Analyst Coverage - Risers & Fallers - NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Updated Analyst CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP). According to the latest broker reports outstanding on Tuesday 5th of April, 0 analysts have a rating of “strong buy”, 0 ...
04/03/16 03:33 PMAfter Last Week What Do Analysts Think Of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) - Share Trading News - After Last Week What Do Analysts Think Of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP)Share Trading News09/10/2014 – NPS Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 36 price target on the stock. The share price of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) was up +0.00% during the ...
04/01/16 03:59 PMMorning Broker Update: NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) - Share Trading News - Morning Broker Update: NPS Pharmaceuticals, Inc. (NASDAQ:NPSP)Share Trading News09/10/2014 – NPS Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 36 price target on the stock. The share price of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) was up +0.00% during the ...and more »
03/30/16 03:55 PMNPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Updated Broker Ratings - Risers & Fallers - NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Updated Broker RatingsRisers & FallersA number of investment brokers have recently updated their price targets on shares of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP). According to the latest broker reports outstanding on Wednesday 30th of March, 0 analysts have a rating of “strong buy”, ...and more »
03/28/16 08:40 PMThis Weeks Broker Price Targets For NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) - Share Trading News - This Weeks Broker Price Targets For NPS Pharmaceuticals, Inc. (NASDAQ:NPSP)Share Trading News11/11/2014 – NPS Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Brean Capital. They now have a USD 41 price target on the stock. 10/24/2014 – NPS Pharmaceuticals, Inc. was downgraded to “neutral” by analysts at Goldman Sachs.and more »
03/28/16 03:33 PMSmart-Money Healthcare Investing Focuses On Major Biotech Stocks - Seeking Alpha - Seeking AlphaSmart-Money Healthcare Investing Focuses On Major Biotech StocksSeeking AlphaFew technology areas are advancing as rapidly as those in the biotechnology arena, where major advances in life sciences are developing significant new treatment approaches for critical ailments. Investment researchers skilled and educated in these ...and more »
03/21/16 03:55 PMNew Broker Ratings For NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) - FTSE News - New Broker Ratings For NPS Pharmaceuticals, Inc. (NASDAQ:NPSP)FTSE News09/10/2014 – NPS Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 36 price target on the stock. The share price of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) was up +0.00% during the ...
03/18/16 03:51 PMNPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Updated Price Targets - Share Trading News - NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Updated Price TargetsShare Trading News11/11/2014 – NPS Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Brean Capital. They now have a USD 41 price target on the stock. 10/24/2014 – NPS Pharmaceuticals, Inc. was downgraded to “neutral” by analysts at Goldman Sachs.and more »
03/15/16 03:46 PMNPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Analyst Updates - Risers & Fallers - NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP). According to the latest broker reports outstanding on Tuesday 15th of March, 0 analysts have a rating of “strong buy”, ...
03/11/16 03:30 PMNPS Pharmaceuticals, Inc. (NASDAQ:NPSP) New Analyst Ratings ... - Share Trading News - NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) New Analyst Ratings ...Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP). The latest reports which are ...and more »
03/04/16 03:22 PMNPS Pharmaceuticals, Inc. (NASDAQ:NPSP) New Analyst Ratings - Share Trading News - NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) New Analyst RatingsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP). The latest reports which are currently in issue on Friday 4th of March state 0 analysts have a rating of “strong buy”, 0 ...NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Broker ViewsRisers & Fallersall 9 news articles »
03/03/16 03:22 PMNPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Broker Views - Risers & Fallers - NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Broker ViewsRisers & FallersA number of investment brokers have recently updated their price targets on shares of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP). According to the latest broker reports outstanding on Thursday 3rd of March, 0 analysts have a rating of “strong buy”, ...
02/25/16 03:46 PMNPS Pharmaceuticals, Inc. Company Profile - Those suffering from intestinal failure are rooting for NPS Pharmaceuticals. The drug development company has a handful of candidates in development for gastrointestinal and endocrine disorders, focusing on rare conditions with few available treatment options.
02/19/16 08:01 AMChancery OKs Shareholder Deal On $5.2B NPS-Shire Sale - Law360, Wilmington (February 18, 2016, 9:10 PM ET) -- A settlement in a class action challenge to the $5.2 billion sale of NPS Pharmaceuticals Inc. to Shire PLC survived a run through Delaware Chancery Court’s new Trulia precedent gantlet on Thursday ...
02/16/16 07:58 AMRecent Broker Updates On NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) - Risers & Fallers - Recent Broker Updates On NPS Pharmaceuticals, Inc. (NASDAQ:NPSP)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP). The latest broker reports which are currently outstanding on Tuesday 16th of February state 0 analysts have a rating of “strong ...and more »
02/11/16 02:48 PMShire Delivers Record Full-year Revenue & Strong Double Digit Growth In Non GAAP Diluted Earnings Per ADS. Las Vegas Blog - (2) On a Constant Exchange Rate (“CER”) basis, which is a Non GAAP measure. (3) Product sales in addition to NPS Pharmaceuticals Inc. (“NPS”) acquired on Feb. 21, 2015. (4) Non GAAP earnings before interest, tax, depreciation & amortization ...
02/11/16 08:02 AMShire Fourth-Quarter Earnings Exceed Analysts' Expectation - Shire Plc, the drugmaker that agreed to buy Baxalta Inc. for $32 billion last month ... for at least $5.9 billion Foresight Biotherapeutics in August for $300 million NPS Pharmaceuticals in January 2014 for $5.2 billion
02/05/16 02:40 PMLatest Analysts Reports On NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) - Risers & Fallers - Latest Analysts Reports On NPS Pharmaceuticals, Inc. (NASDAQ:NPSP)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP). Most recent broker ratings. 01/27/2015 – NPS Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at Wedbush.and more »
01/16/16 02:45 PMBaxalta acquired by Shire Pharmaceuticals - Last year Shire acquired NPS Pharmaceuticals for $5.2 billion and Dyax for $5.9 ... Baxalta’s tax-free status resulting from its spin-off from Baxter International Inc. last year. “We came out without any doubt that this was not jeopardizing the ...
02/16/15 12:00 PMWill NPS Pharmaceuticals (NPSP) Miss on Earnings in Q4? - Analyst Blog -
02/13/15 08:54 AMShire Misses on Q4 Earnings, Revenues Beat; Shares Rise - Analyst Blog -
02/12/15 09:45 AMShire Moves Up On NPS Potential; Q4 Earnings Miss -
02/12/15 08:14 AMShire confident on 2015 after NPS deal, binge-eating drug approval -
02/12/15 06:17 AMShire sees mid-single earnings growth in 2015 -
01/26/15 02:43 AMShire target NPS Pharma wins FDA approval for Natpara -
01/26/15 02:16 AMShire shares jump as drug approval vindicates $5.2 bln NPS purchase -
01/23/15 06:39 PMU.S. FDA approves NPS drug, in move validating Shire takeover deal -
01/23/15 06:00 PMFDA approves NPS drug, in move validating Shire takeover deal -
01/12/15 07:32 PM[video]Jim Cramer's 'Mad Money' Recap: Blame Tech, Oil and Retail for Today's Losses -
01/12/15 03:45 PMU.S. equities end lower... -
01/12/15 07:18 AMShire acquires US rival NPS Pharmaceuticals for $5.2bn -
01/12/15 05:21 AMNPS a "natural fit" for pharma group Shire, says UBS -
01/12/15 04:17 AMCramer: Hold Your Fire -
01/11/15 02:27 PMShire to buy NPS for $5.2 billion to boost rare disease drugs -
01/11/15 02:25 PMShire to buy NPS for $5.2 bln to boost rare disease drugs -
01/11/15 12:27 PMShire to buy specialty drugmaker NPS Pharma for $5.2 billion -
12/17/14 11:06 AMShire considering bid for NPS Pharmaceuticals - Bloomberg -

Social

About NPS Pharmaceuticals

NPS Pharmaceuticals logoNPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on delivering therapies that transform the lives of patients with rare diseases. The Company's primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved the United States Food and Drug Administration (FDA) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The Company's second principal product, Natpara (recombinant human parathyroid hormone 1-84 [rDNA origin] injection, has been developed for hypoparathyroidism, a rare multidimensional disorder characterized by deficient or absent parathyroid hormone (PTH). The Company has collaborations or royalty agreements with Amgen, Janssen, GlaxoSmithKline and Kyowa Hakko Kirin.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: NPSP
  • CUSIP: 62936P10
Key Metrics:
  • Previous Close: $46.00
  • 50 Day Moving Average: $0
  • 200 Day Moving Average: $37
  • P/E Ratio: N/A
  • P/E Growth: 0
  • Market Cap: $N/A
  • Current Year EPS Consensus Estimate: $1 EPS
  • Next Year EPS Consensus Estimate: $2 EPS
Additional Links:
NPS Pharmaceuticals (NASDAQ:NPSP) Chart for Sunday, July, 24, 2016